Top Story

Morning Read: EMR vendor grades are in (it doesn’t look good)

Also, the Mylan-Perrigo hostile takeover is underway, Medtronic gets an FDA approval and new population health innovations are popping up throughout the country.


Healthcare IT News released its EHR satisfaction survey results. The TL;DR version: no one gets higher than a 7.6 out of 10, Epic gets the highest rankings for interoperability, and I found the comments more entertaining than the data.

If these were grades in school with 10 = 100%, all the vendors would have failed except for one and they would only have received a D. What does this tell you? It tells me that these vendors aren’t listening to their customers. Wow, look at the failing customer support numbers. Terrible, terrible, terrible. The CEO’s of these companies are extremely mistaken if they feel they are doing a good job after looking at these kinds of numbers. I’m sure many excuses will be forthcoming, such as blaming the ONC, CMS and others but the blame is squarely on the shoulders of these companies. You’ve enriched yourselves by overcharging for poorly performing systems that still won’t talk to each other well or at all. You’ve all failed in my opinion. Get your collective acts together already. Geez

Healthcare IT News, Healthcare IT News

Mylan launched its hostile bid for Perrigo. At $27 billion, it’s $8 billion less than what it offered in April (Mylan’s stock has dropped by more than one-third in the last three months). – Wall Street Journal


Swiss medical device company Symetis has set its IPO at a minimum of $16.16. – Reuters

Terrible news. Cardiovascular Systems CEO David Martin has been diagnosed with stomach cancer. – Star Tribune

Aclaris Therapeutics added $40 million and acquired a set of compounds from Rigel Pharmaceuticals. – Philadelphia Business Journal

FDA has put a hold on Forum Pharmaceuticals’ Alzheimer’s trials after some severe gastrointestinal reactions. – FierceBiotech

Medtronic’s MRI-safe cardiac defibrillator, Evera MRI SureScan, has won FDA approval. – MassDevice

Biopharma Trevena wants to add another $63.4 million through a public stock sale this week. Mirati Therapeutics plans an $80 million sale in about two weeks. – Philadelphia Business Journal, PRNewswire

Here’s a rundown of the new St. Jude Medical management team. – BusinessWire

Physio-Control has purchased Northern Ireland’s HeartSine Technologies, which makes automated external defibrillators. – BusinessWire

Myriad Genetics has a new logo. The rebranding is heavy on the consumer-empowerment angle. What do you think?



The new Oregon Center for Health Innovation will study population health innovations, among other things. – Portland Business Journal

Patient engagement on the grassroots level: A doctor goes to the barber shop to improve public health. – Huffington Post

A $200 billion opportunity: the need to refurbish or outright redesign healthcare facilities. – Futurity

Long Shore-Long Island Jewish Health System is now …. Northwell Health. – Newsday

Here’s how population health can better support chronic asthma management. – Brookings

Aspirin gets an early nod as a cancer preventer. – The New York Times

UnitedHealthcare has a new CEO for its New Mexico and Arizona markets: David Allazetta – Phoenix Business Journal


Japanese startup Moff has raised $1.3 million from video game makers to develop its child-focused wearable. – mobihealthnews

COMS Interactive has upgraded its disease care management system, Daylight IQ. – PRNewswire


The FDA has revamped its foreign office staff, including new directors in China, Europe, India and Latin America. – RAPS

Rhode Island is turning into a cautionary tale against using state dollars to fund early-stage companies. Life science startup Nabsys has shut down and now all hell has broken loose for the state and Gov. Gina Raimondo, who used to run the venture firm that also funded Nabsys. – GoLocalProv, GoLocalProv

A majority of House members have co-sponsored a bill to repeal the Cadillac tax (which means nothing). – PRNewswire


Fascinating data breakdown of corporate venture capital term sheets across all sectors: they lead more rounds than ever before and their terms look more like traditional VC sheets. But, they remain extremely company friendly.

CB Insights